Using scans to predict PSMA therapy response in prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study is testing whether a special scan (dosimetry) can help predict how well PSMA radioligand therapy works for men with advanced prostate cancer that has spread. The therapy uses a radioactive drug to target and kill cancer cells that have a protein called PSMA.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man 18 years or older with prostate cancer.
- Your cancer has spread to other parts of your body (metastatic) and is getting worse (rising PSA, new bone lesions, or tumor growth).
- You are being considered for a treatment called PSMA radioligand therapy (177Lu-PSMA-RLT).
- You must have at least one tumor that shows high PSMA activity on a PSMA PET/CT scan (stronger than normal liver activity).
- You are able to start this treatment within 4 weeks of that PSMA PET/CT scan.
- You are willing to follow all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new imaging approach during treatment with a radioactive drug (Lu-PSMA) for men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if imaging changes can help predict how well the treatment is working.
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This study looks at how well a type of imaging scan called SPECT can predict treatment response in people who have already received at least two cycles of the therapy 177Lu-PSMA for advanced prostate cancer. It may help doctors understand how well the treatment is working and when to expect results.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.